Genetic Variants in DNA Mismatch Repair Pathway predict prognosis of Lung Cancer patients with receiving Platinum-Based Chemotherapy.

导出 OA

翻译打印收藏纠错

作者： Jun-Yan,Liu ^[1] ; Ting,Zou ^[2] ; Ji-Ye,Yin ^[3] ; Zhan,Wang ^[4] ; Ying,Wang ^[5] ; Zhao-Qian,Liu ^[6] ; Juan,Chen ^[2] ; Zhi-Wei,Chen ^[3]

作者单位： Department of Orthopaedics, The First Affiliated Hospital of the University of South China, Hengyang 421001, China. ^[1] National Institution of Drug Clinical Trial, Xiangya Hospital, Central South University, Changsha, Hunan, P.R.China. ^[2] Departments of Clinical Pharmacology, Xinagya Hospital, Central South University, Changsha 410008, China. ^[3] Institute of Clinical Pharmacology and Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China. ^[4] Department of Medical Oncology, Lung cancer and Gastrointestinal unit, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha 410013, China. ^[5] Hunan clinical research center in gynecologic cancer, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha 410013, China. ^[6] Department of Pharmacy, Xinagya Hospital, Central South University, Changsha 410008, China. ^[7]

关键词 SAPCD1 DNA mismatch repair MSH2 genetic polymorphisms lung cancer platinum-based chemotherapy prognosis

DOI 10.7150/jca.46150

PMID 32742474

发布时间 2020-10-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交